ERBB2 and breast cancer: Trastuzumab improves survival outcomes when added to chemotherapy for the treatment of patients with HER2-positive early breast cancer (EBC) [6], HER2-positive metastatic breast cancer (MBC) [7], and HER2-positive metastatic gastric or gastroesophageal junction cancer [8].